Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo and Ranbaxy Laboratories are set to widen their Hybrid Business Model with the launch of Olmesartan medoxomil in Mexico.
Subscribe to our email newsletter
Olmesartan medoxomil, a member of the angiotensin receptor blocker (ARB) class of antihypertensive medications, is indicated for the treatment of hypertension.
The companies’ Mexican subsidiaries Daiichi Sankyo Mexico and Ranbaxy Mexico will leverage the group’s Hybrid Business Model to offer generic medicines in the country.
The group expects to roll out the drug in 2011.
Daiichi Sankyo president and CEO Joji Nakayama said they are determined to work with Ranbaxy to further serve diversifying medical needs in this strongly emerging market.
Ranbaxy managing director Arun Sawhney said Ranbaxy and Daiichi Sankyo will work together in providing innovative options and solutions to customers through the Hybrid Business Model.